期刊文献+

精神分裂症患者心血管疾病风险因素的研究进展 被引量:21

Cardiovascular diseases among patients with schizophrenia
在线阅读 下载PDF
导出
摘要 精神分裂症伴随的躯体疾病尤其是心血管疾病是近年来临床医生和研究人员逐渐关注的领域。了解精神分裂症与心血管疾病之间的关系,减轻精神分裂症患者的疾病负担,提高精神分裂症患者的生活质量,是精神科临床工作的重中之重。该综述的目的是概述精神分裂症患者心血管疾病的相关危险因素及潜在的早期诊断方法和预防措施,并讨论了早期发现和预防精神分裂症心血管疾病发生的潜在可行的方法。尽管精神分裂症患者是罹患心血管疾病的高危人群,但目前仍缺乏针对精神分裂症心血管疾病早期发现和预防的具有共识性的治疗指南。精神分裂症患者合并心血管疾病问题需要更多的临床医生和研究人员关注。 The presence of comorbid physical illnesses,especially cardiovascular diseases(CVD)in schizophrenia is a growing area of concern in recent years.In order to reduce disease burden,improve quality of life and provide holistic care,it is important to understand the relationship between schizophrenia and CVD.The objective of this review is to explore the extent of CVD problems,relevant risk factors and potential measures for early diagnosis and prevention of CVD among patients with schizophrenia.The potential methods for early detection and prevention of CVD in schizophrenia are also discussed.Though the patients with schizophrenia form a high risk group for CVD,consensus guidelines for early detection and prevention of CVD in schizophrenia are lacking.Comorbidity of CVD in schizophrenia needs more serious attention by clinicians and researchers.
作者 赵帅 周晓琴 ZHAO Shuai;ZHOU Xiaoqin(Department of Psychiatry,Anhui Medical University,Hefei,Anhui 230032,China;Department of Psychiatry,Chaohu Hospital of Anhui Medical University,Chaohu,Anhui 238000,China)
出处 《安徽医药》 CAS 2018年第4期591-595,共5页 Anhui Medical and Pharmaceutical Journal
关键词 精神分裂症 心血管疾病 代谢综合征 schizophrenia cardiovascular disease metabolic syndrome
  • 相关文献

参考文献1

二级参考文献15

  • 1Kuehn BM. Questionable antipsyehotic prescribing remains common,despite serious risks[J]. JAMA,2010,303:1582-1584.
  • 2Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease [ J ]. Am Heart J, 2005, 150:1115-1121.
  • 3Saddichha S, Manjunatha N, Ameen S, et al. Metabolic syndrome in first episode schizophrenia:a randomized double-blind controlled, short-term prospective study [ J ]. Schizophr Res, 2008,101 : 266- 272.
  • 4Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antip-sychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial[ J ]. Lancet,2008,371 : 1085-1097.
  • 5Perez-Iglesias R, Crespo-Facorro B, Amado JA, et al. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with halopefidol, olanzapine, or risperidone [ J ]. J Clin Psychiatry, 2007,68 : 1735- 1740.
  • 6Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, et al. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year:findings of a randomized clinical trial in a drug-naive population [ J ]. Schizophr Res ,2008 ,99 :13-22.
  • 7Graham KA, Cho H, Brownley KA, et al. Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects [ J ]. Schizophr Res, 2008, 101 : 287- 294.
  • 8Correll CU, Frederickson AM, Kane JM, et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome [ J ] ? Sehizophr Res ,2007,89:91-100.
  • 9Hennekens CH. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia [ J ]. J Clin Psychiatry,2007,68 ( Suppl 4) :4-7.
  • 10Capasso RM,Lineberry TW,Bostwick JM, et al. Mortality in schizo- phrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort -1950-2005 [J]. Schizophr Res ,2008,98:287-294.

共引文献8

同被引文献185

引证文献21

二级引证文献113

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部